DDAVP INDUCED HYPONATREMIA FOR TREATMENT OF OLIGOHYDRAMNIOS

DDAVP 诱导低钠血症治疗低钠血症

• 批准号: 6278390
• 负责人: Michael Glenn Ross
• 金额: $ 3.92万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6278390
• 关键词: amniotic fluid; clinical research; female; hormone therapy; human pregnant subject; human subject; human therapy evaluation; hyponatremia; pregnancy disorder; urination; vasopressins

Despite the significant consequences of oligohydramnios there are few clinical approaches to increase amniotic fluid. Recent studies indicate the potential utility of a novel treatment for oligohydramnios using maternal DDAVP administration to increase fetal urine flow. DDAVP causes the maternal and fetal kidney to excrete a lower volume of more concentrated urine. As the mother retains water, maternal and fetal plasma osmolality is reduced and fetal urine flow is increased. This study will examine the long term effect of maternal DDAVP.

尽管羊水过少的后果很严重，但很少有 增加羊水的临床途径。最近的研究表明 羊水过少的一种新治疗方法的潜在应用 孕妇应用DDAVP以增加胎儿尿流量。DDAVP原因 母体和胎儿的肾脏排泄量较低，较多 浓缩尿液。当母亲保留水分时，母体和胎儿 血浆渗透压降低，胎儿尿流量增加。这 研究将检查母亲DDAVP的长期影响。